Tavneos: Rare disease drug recalled in Republic of Ireland
Amgen's drug Tavneos (Avacopan), used for rare autoimmune diseases, is recalled in Ireland following a recommendation by the European Medicines Agency. The recall comes after reports of 20 deaths in Japan, though causality is unclear. The European Commission endorsed the recall, and France and the UK are also reviewing the drug. The HPRA advises patients not to stop treatment without consulting doctors.
How this was made
The 30-second read
Why it matters
The recall may reduce Amgen's revenue from the drug and increase litigation risk, while also prompting investors to reassess other rare disease assets.
Market read
Regulatory recall of a flagship rare disease drug could pressure Amgen's share price and affect the broader biotech sector.
What to watch
Potential insurance recoveries or rapid regulatory clearance for other indications could mitigate impact.
Background
Tavneos (avacopan) is used for rare autoimmune vasculitis; recent deaths in Japan raised safety concerns, prompting EU regulators to act.
Ticker impact
Amgen's Tavneos (avacopan) recall in Ireland and EU regulatory actions.
Downside pressure expected pending further regulatory updates.
Recall signals safety issues; EU regulators have stripped market authorisation, which could affect sales and reputation.
Market effects
Biotech and rare disease drug sector may see heightened scrutiny.
European markets could react to regulatory actions; Irish and UK pharma stocks may feel spillover.
Amgen is a large US biotech; recall could influence global investor sentiment toward similar therapies.
Counterpoint
If the recall is limited to specific batches, broader product pipeline may remain unaffected.
Key entities
- CompanyAmgen
US biotech manufacturer of Tavneos.
- RegulatorHPRA
Health Products Regulatory Authority of Ireland overseeing the recall.
